Biogen $BIIB
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS23
PHASE 3 / 2-317
RECRUITING8
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO40%
Delay Index: of 15 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.3 months). See all sponsors →
Open Biogen on the live radar map → 📅 $BIIB readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| CELIA NCT05399888 |
P2 | Active, not recruiting | Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease Dementia | 416 | 2026-03-11 (-9 mo) |
| TOPAZ-2 NCT04961567 |
P3 | Active, not recruiting | Lupus Erythematosus, Systemic | 562 | 2026-09-27 (+15 mo) |
| TOPAZ-1 NCT04895241 |
P3 | Active, not recruiting | Lupus Erythematosus, Systemic | 548 | 2026-09-30 (+18 mo) |
| AMETHYST NCT05531565 |
P2/3 | Active, not recruiting | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | 450 | 2026-10-20 (+3 mo) |
| TRANSCEND NCT06685757 |
P3 | Active, not recruiting | Antibody-mediated Rejection | 132 | 2026-12-01 |
| BIIB017 (peginterferon beta-1a) NCT03958877 |
P3 | Active, not recruiting | Multiple Sclerosis, Relapsing-Remitting | 152 | 2027-05-20 (+50 mo) |
| PREVAIL NCT06935357 |
P3 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 454 | 2027-05-31 |
| ATLAS NCT04856982 |
P3 | Active, not recruiting | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | 158 | 2027-08-07 (+12 mo) |
| ASCEND NCT05067790 |
P3 | Active, not recruiting | Spinal Muscular Atrophy | 45 | 2027-09-24 (+3 mo) |
| BRAVE NCT06953583 |
P3 | Active, not recruiting | Friedreich Ataxia | 255 | 2027-11-16 |
| GRAVITATE NCT07722546 |
P2 | Recruiting | Graves' Disease | 60 | 2028-01-31 |
| TRANSPIRE NCT07219043 |
P2 | Recruiting | Microvascular Inflammation | 81 | 2028-02-10 |
| SOLAR NCT07444476 |
P3 | Recruiting | Spinal Muscular Atrophy | 90 | 2028-06-23 |
| Felzartamab NCT07889362 |
P2 | Not yet recruiting | Immunoglobulin A Nephropathy | 25 | 2028-08-13 |
| MYAMERGE NCT07939802 |
P2 | Not yet recruiting | Generalized Myasthenia Gravis | 75 | 2028-09-19 |
| STELLAR-1 NCT07221669 |
P3 | Recruiting | Muscular Atrophy, Spinal | 30 | 2028-11-28 |
| AMETHYST LTE NCT06044337 |
P3 | Enrolling by invitation | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | 306 | 2029-06-26 |
| STELLAR-2 NCT07444450 |
P3 | Recruiting | Muscular Atrophy, Spinal | 42 | 2029-07-27 |
| PROMINENT NCT06962800 |
P3 | Recruiting | Primary Membranous Nephropathy | 180 | 2030-01-28 (+13 mo) |
| Felzartamab NCT07444489 |
P3 | Enrolling by invitation | Antibody-mediated Rejection; Microvascular Inflammation | 201 | 2031-12-31 |
| EMERALD NCT05352919 |
P3 | Enrolling by invitation | Systemic Lupus Erythematosus (SLE) | 864 | 2032-05-03 (+43 mo) |
| HORIZON NCT07855211 |
P1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 69 | 2034-01-23 |
| VOYAGE NCT07483632 |
P3 | Not yet recruiting | Relapsing Forms of Multiple Sclerosis | 185 | 2034-07-28 |